GlassScriptPhysician profile
Abby Skripko
NPI 1164836144
$4,378.92
in general payments reported to CMS, 2019-2025
36 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,398 · 2022: $1,175 · 2023: $1,349 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.38 |
| Education | $277.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $624.15 | 2021-2025 | Opdivo |
| Incyte Corporation | $355.14 | 2021-2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $346.81 | 2021-2023 | Calquence |
| Seagen INC. | $299.62 | 2021-2023 | Tukysa, Padcev |
| Novartis Pharmaceuticals Corporation | $248.61 | 2022-2023 | |
| Janssen Biotech, INC. | $197.10 | 2025 | Rybrevant, Erleada |
| Genzyme Corporation | $182.87 | 2021-2023 | |
| Amgen INC. | $177.04 | 2021-2023 | Lumakras |
| Celgene Corporation | $171.44 | 2021-2023 | Pomalyst |
| Pfizer INC. | $162.09 | 2021-2023 | |
| Sobi, INC | $141.79 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $126.61 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $124.04 | 2021-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $111.52 | 2021-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $111.12 | 2021-2023 | Enhertu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Genentech USA, INC. | $99.90 | 2022-2023 | Venclexta, Lunsumio, Gazyva |
| Emd Serono, INC. | $84.97 | 2021-2023 | Bavencio |
| Jazz Pharmaceuticals INC. | $77.23 | 2022-2025 | |
| Lilly USA, LLC | $70.25 | 2022-2023 | Verzenio, Jaypirca |
| Foundation Medicine, INC. | $62.99 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $61.12 | 2021-2025 | Onivyde |
| Taiho Oncology, INC. | $56.83 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $54.32 | 2021-2025 | Lynozyfic |
| Bayer Healthcare Pharmaceuticals INC. | $43.70 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $37.06 | 2021-2023 | Xpovio |
| Morphosys, US INC. | $35.39 | 2022-2023 | Monjuvi |
| Rigel Pharmaceuticals, INC. | $35.38 | 2022-2023 | Tavalisse, Rezlidhia |
| Kite Pharma, INC. | $33.70 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $32.18 | 2021 | |
| Eisai INC. | $31.56 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $19.99 | 2022 | |
| Beigene USA, INC. | $19.74 | 2023 | Brukinsa |
| Agios Pharmaceuticals, INC. | $15.71 | 2023 | Pyrukynd |
| Dova Pharmaceuticals | $13.82 | 2021 | |
| Astellas Pharma US INC | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Skripko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.